Wednesday, Teva revealed booming third-quarter sales for its generics and biosimilars. In the U.S., revenue from the knockoffs came in at $1.1 billion, which was a 30% increase year over year, or ...

Shares of Teva Pharmaceutical (NYSE:TEVA) gained in the premarket trading on Wednesday after the generic drugmaker reported better-than-expected Q3 2024 financials and raised its full-year outlook ...

Teva Pharmaceuticals (NYSE:TEVA) just served up some serious growth numbers in its Q3 2024 report, turning heads with a $4.3 billion revenuea 13% boost from last year's numbers. With its U.S ...

With Donald Trump now poised to become U.S. president for the second time in January, biotech and pharmaceutical leaders are preparing for the shift to an administration with a complicated history ...

The United States Department of Justice (DOJ) recently announced that Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. will pay $450 million to resolve allegations of violating the ...

On October 31, 2024, the European Commission issued a fine of €462.6 million to Teva Pharmaceuticals, citing abuse of its market dominance by delaying competition for Copaxone, a leading multiple ...

Copyright 2024 The Associated Press. All Rights Reserved. FILE - Israeli flag flies outside Teva Pharmaceutical facility building in Neot Hovav, Israel, on Dec. 14 ...

European Union antitrust authorities fined Israel’s Teva Pharmaceuticals TEVA0.41%increase; green up pointing triangle 462.6 million euros ($502.3 million), saying the company abused its market ...

Some two years after the European Commission accused Teva of meddling with the competition for its former multiple sclerosis blockbuster Copaxone, the other shoe has finally dropped. The European ...

Teva (TEVA) Pharmaceuticals Industries is responding to the European Decision following its investigation into the company’s practices regarding COPAXONE — the standard-of-care treatment for m ...